Double de novo mutations of ELANE (ELA2) in a patient with severe congenital neutropenia requiring high-dose G-CSF therapy.

@article{Lundn2009DoubleDN,
  title={Double de novo mutations of ELANE (ELA2) in a patient with severe congenital neutropenia requiring high-dose G-CSF therapy.},
  author={Lina Lund{\'e}n and Sandra Boxhammer and G{\"o}ran Carlsson and Karl-Gustav Ellstr{\"o}m and Magnus Nordenskj{\"o}ld and Kristina Lagerstedt-Robinson and Bengt Fadeel},
  journal={British journal of haematology},
  year={2009},
  volume={147 4},
  pages={587-90}
}
2006; Spaner & Masellis, 2007). Here we showed that all the myeloid leukaemia cell lines tested in this study expressed various members of TLRs. Stimulation by the ligands, however, did not trigger their differentiation as was observed in normal bone marrow progenitors. Most established leukaemia cell lines may acquire irreversible changes that make cells resistant to TLR ligand stimulation. Although the phenomenon called spontaneous remission associated with infection is rare, it would be… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
1 Extracted Citations
4 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.

Similar Papers

Loading similar papers…